ZIKAlliance is a multinational and multi-disciplinary research consortium comprised of 54 partners worldwide and coordinated by Inserm, the French National Institute of Health and Medical Research. ZIKAlliance is funded by the European Union's Horizon 2020 Research and Innovation Programme. The project will investigate clinical, fundamental, environmental and social aspects of ZIKV infection. In particular, ZIKAlliance will focus on the impact of ZIKV infection during pregnancy and the natural history of ZIKV in humans and their environment. In collaboration with two other EC funded consortia (ZikaPLAN and ZIKAction), ZIKAlliance will also work on the development of a preparedness platform in Latin America and the Caribbean.
Upcoming webinar: WHO Launches New Clinical Trial Guidance –
|
|
ZIKAlliance project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement N.734548
Summary Background Knowledge regarding the risks associated with Zika virus (ZIKV) infections in pregnancy has relied on individual studies with relatively small sample sizes and variable risk estimates of adverse ...
In low-resource settings, resilience to infectious disease outbreaks can be hindered by limited access to diagnostic tests. Here we report the results of double-blinded studies of the performance of paper-based ...
RSC Medicinal Chemistry, 5 July 2021 Summary The identification of specific biomarkers for Zika infection and its clinical complications is fundamental to mitigate the infection spread, which has been ...
Pedro Kourí Institute of Tropical Medicine, as PAHO / WHO Collaborating Center for the Study of Dengue and its Control, the Cuban Society of Microbiology and Parasitology, and the Ministry of Public Health of the Republic of Cuba are pleased ... Read more